概 要
本研究通过比较间歇性跛行 (IC) 和严重肢体缺血 (CLI) 患者的血液参数, 选择合适的临床和生化特指标, 以评估促血管生成的潜力和抑制血管生成的作用。 结果表明, 通过刺激下肢动脉疾病 (LEAD) 病人血浆中的血管生成, 内皮生长因子 A (VEGF-A) 浓度会显著增加, 同时依赖于循环受体 sVEGFR-1 和 sVEGFR-2 的抑制也会显著减少。 与 IC 病人相比, CLI 病人具有较高的 VEGF-A、 金属蛋白酶 9 (MMP-9) 、 金属蛋白酶组织抑制因子 1 (TIMP-1) 和 TIMP-2 浓度。
Article PDF
Avoid common mistakes on your manuscript.
References
Baczynska D, Michalowska D, Barc P, et al., 2016. The expression profile of angiogenic genes in critical limb ischemia popliteal arteries. J Physiol Pharmacol, 67(3):353–362.
Baum O, Ganster M, Baumgartner I, et al., 2007. Basement membrane remodeling in skeletal muscles of patients with limb ischemia involves regulation of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases. J Vasc Res, 44(3):202–213. https://doi.org/10.1159/000100376
Bogaczewicz J, Dudek W, Zubilewicz T, et al., 2006. The role of matrix metalloproteinases and their tissue inhibitors in angiogenesis. Pol Mer Lek, 21(121):80–85 (in Polish).
Busti C, Falcinelli E, Momi S, et al., 2010. Matrix metalloproteinases and peripheral arterial disease. Int Emerg Med, 5(1):13–25. https://doi.org/10.1007/s11739-009-0283-y
Chase AJ, Newby AC, 2003. Regulation of matrix metalloproteinase (matrixin) genes in blood vessels: a multi-step recruitment model for pathological remodelling. J Vasc Res, 40(4):329–343. https://doi.org/10.1159/000072697
de Caridi G, Massara M, Spinelli F, et al., 2016. Matrix metalloproteinases and risk stratification in patients undergoing surgical revascularisation for critical limb ischaemia. Int Wound J, 13(4):493–499. https://doi.org/10.1111/iwj.12464
Findley CM, Mitchell RG, Duscha BD, et al., 2008. Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease. J Am Coll Cardiol, 52(5):387–393. https://doi.org/10.1016/j.jacc.2008.02.045
Fink K, Boratyński J, 2012. The role of metalloproteinases in modification of extracellular matrix in invasive tumor growth, metastasis and angiogenesis. Post Hig Med Dosw, 66:609–628. https://doi.org/10.5604/17322693.1009705
Groblewska M, Tycińska A, Mroczko B, et al., 2011. The role of matrix metalloproteinases in cardiovascular diseases. Pol Merk Lek, 30(178):235–240 (in Polish).
Herman MP, Sukhova GK, Kisiel W, et al., 2001. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J Clin Invest, 107(9):1117–1126. https://doi.org/10.1172/jci10403
Hobeika MJ, Edlin RS, Muhs BE, et al., 2008. Matrix metalloproteinases in critical limb ischemia. J Surg Res, 149(1):148–154. https://doi.org/10.1016/j.jss.2007.08.004
Hrabec E, Naduk J, Strek M, et al., 2007. Type IV collagenases (MMP-2 and MMP-9) and their substrates-intracellular proteins, hormones, cytokines, chemokines and their receptors. Post Biochem, 53(1):37–45 (in Polish).
Jazwa A, Florczyk U, Grochot-Przeczek A, et al., 2016. Limb ischemia and vessel regeneration: is there a role for VEGF? Vascul Pharmacol, 86:18–30. https://doi.org/10.1016/j.vph.2016.09.003
Kugler A, 1999. Matrix metalloproteinases and their inhibitors. Anticancer Res, 19(2C):1589–1592.
Lalu MM, Pasini E, Schulze CJ, et al., 2005. Ischaemiareperfusion injury activates matrix metalloproteinases in the human heart. Eur Heart J, 26(1):27–35. https://doi.org/10.1093/eurheartj/ehi007
Lipka D, Boratyński J, 2008. Metalloproteinases. Structure and function. Post Hig Med Dosw, 62:328–336 (in Polish).
Liu P, Sun M, Sader S, 2006. Matrix metalloproteinases in cardiovascular disease. Can J Cardiol, 22(Suppl B):25B–30B. https://doi.org/10.1016/s0828-282x(06)70983-7
Rajzer M, Wojciechowska W, Kameczura T, et al., 2017. The effect of antihypertensive treatment on arterial stiffness and serum concentration of selected matrix metalloproteinases. Arch Med Sci, 13(4):760–770. https://doi.org/10.5114/aoms.2016.58825
Rundhaug JE, 2005. Matrix metalloproteinases and angiogenesis. J Cell Mol Med, 9(2):267–285. https://doi.org/10.1111/j.1582-4934.2005.tb00355.x
Signorelli SS, Anzaldi M, Libra M, et al., 2016. Plasma levels of inflammatory biomarkers in peripheral arterial disease: results of a cohort study. Angiology, 67(9):870–874. https://doi.org/10.1177/0003319716633339
Stehr A, Töpel I, Müller S, et al., 2010. VEGF: a surrogate marker for peripheral vascular disease. Eur J Vasc Endovasc Surg, 39(3):330–332. https://doi.org/10.1016/j.ejvs.2009.09.025
Tayebjee MH, Tan KT, MacFadyen RJ, et al., 2005. Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: relationship to disease severity. J Intern Med, 257(1):110–116. https://doi.org/10.1111/j.1365-2796.2004.01431.x
Vitlianova K, Georgieva J, Milanova M, et al., 2015. Blood pressure control predicts plasma matrix metalloproteinase-9 in diabetes mellitus type II. Arch Med Sci, 11(1):85–91. https://doi.org/10.5114/aoms.2015.49208
Wu HY, Shou XL, Liang L, et al., 2016. Correlation between plasma angiopoietin-1, angiopoietin-2 and matrix metalloproteinase-2 in coronary heart disease. Arch Med Sci, 12(6):1214–1219. https://doi.org/10.5114/aoms.2016.62909
Zawierucha P, Kempisty B, Sosińska P, et al., 2012. Molecular aspects of angiogenesis and its role in atherosclerosis. Post Biol Kom, 39(4):589–610 (in Polish).
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported by the Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, Poland (No. 3/WF-SD)
Electronic supplementary materials
11585_2019_24_MOESM1_ESM.pdf
Coexistence of proangiogenic potential and increased MMP-9, TIMP-1, and TIMP-2 levels in the plasma of patients with critical limb ischemia
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://doi.org/creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
About this article
Cite this article
Wieczór, R., Wieczór, A.M., Kulwas, A. et al. Coexistence of proangiogenic potential and increased MMP-9, TIMP-1, and TIMP-2 levels in the plasma of patients with critical limb ischemia. J. Zhejiang Univ. Sci. B 20, 687–692 (2019). https://doi.org/10.1631/jzus.B1800373
Published:
Issue Date:
DOI: https://doi.org/10.1631/jzus.B1800373